Elicio Therapeutics, Inc. ELTX

Company Overview

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies designed to enhance the delivery and effectiveness of cancer vaccines and immune-modulating therapeutics. The company operates within the biotechnology and oncology sectors, with a primary emphasis on lymph node-targeted immunotherapies intended to stimulate antigen-specific T-cell responses against solid tumors. Its platform technologies are centered on amphiphile (“AMP”) modification technology, which is designed to improve trafficking of therapeutic compounds to lymph nodes after administration.

The company’s principal product candidates have included ELI-002, an investigational therapeutic cancer vaccine targeting KRAS-driven cancers, particularly pancreatic and colorectal cancers with KRAS mutations. Elicio’s strategy has focused on addressing minimal residual disease and relapse prevention in high-risk oncology settings. The company evolved from earlier platform-development efforts into a more oncology-focused clinical-stage enterprise and became publicly traded through a merger transaction involving Angion Biomedica Corp., after which the combined company adopted the Elicio Therapeutics name and Nasdaq ticker symbol “ELTX.”